• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Merck & Co (NY:MRK)

    148.36 UNCHANGED
    Delayed Quote Updated: 7:00 PM EST, Nov 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Merck & Co

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    99 100 Next >
    News headline image
    Here's Why I Think Every Investor Needs to Invest in These "Miracle" Drugs ↗
    The market for GLP-1 drugs is forecast to explode. It may be understated still. 
    Via The Motley Fool
    News headline image
    Merck to Present New Data from Its Broad Oral HIV Portfolio and Pipeline at HIV Glasgow 2026
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Why Merck Stock Flew Higher on Friday ↗
    Investors were still buying it in the afterglow of its latest quarterly earnings release. 
    Via The Motley Fool
    Topics Intellectual Property
    Merck & Co. (NYSE:MRK) Posts Q3 Earnings Beat as EPS Surprise Offsets In-Line Sales Guidance ↗
    Via Chartmill
    Topics Earnings
    News headline image
    MRK Q3 deep dive: oncology launches, clinical pipeline advances, and margin headwinds
    Global pharmaceutical company Merck (NYSE:MRK) reported revenue ahead of Wall Street’s expectations in Q3 2026, with sales up 4.7% year on year to $18.09 bil... 
    Via StockStory
    News headline image
    Lost Money on Merck & Co., Inc. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 1.76% Share Price Drop
    From Glancy Prongay Wolke & Rotter LLP
    Via Business Wire
    News headline image
    Did You Lose Money on Merck & Co., Inc. Stock? The Law Offices of Howard G. Smith Announces Securities Fraud Investigation After 1.76% Share Price Decline
    From The Law Offices of Howard G. Smith
    Via Business Wire
    News headline image
    Merck & Co., Inc. Q3 Earnings Call Highlights ↗
    Merck & Co., Inc. (NYSE:MRK) reported third-quarter 2026 revenue of $18.1 billion, up 5% from a year earlier, as growth in oncology, vaccines, cardiometabolic products and animal health helped offset... 
    Via MarketBeat
    Topics Earnings
    News headline image
    Lost Money on Merck & Co., Inc. Shares? The Law Offices of Frank R. Cruz Investigates Potential Securities Fraud After 1.76% Stock Decline
    From The Law Offices of Frank R. Cruz
    Via Business Wire
    Dow Jones Top Movers for Oct. 29, 2026: Merck and Nike Lead Gainers, Alphabet and Caterpillar Fall ↗
    Via Chartmill
    Topics Stocks
    News headline image
    Merck (MRK) Q3 2026 Earnings Call Transcript ↗
    Generic headwinds ahead in 2027, but new launches and WINREVAIR growth signal momentum. 
    Via The Motley Fool
    Topics Earnings
    News headline image
    Merck Lifts Outlook on a Lower Tax Rate: Rapid Earnings Reaction ↗
    Merck’s new drugs are growing fast enough to cover generic losses, but part of this quarter’s sales gain won’t last. Here’s what to watch. 
    Via The Motley Fool
    Topics Intellectual Property
    Dow Jones Top Movers Today: 8 Gainers, 4 Losers in Split Session ↗
    Via Chartmill
    Topics Stocks
    News headline image
    Merck (NYSE:MRK) delivers impressive Q3 2026
    Global pharmaceutical company Merck (NYSE:MRK) announced better-than-expected revenue in Q3 2026, with revenue rising 4.7% year on year to $18.09 billion. Th... 
    Via StockStory
    News headline image
    Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2026 Financial Results; Highlights Multiple Milestones Advancing Broad, Diverse Pipeline
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Could Revolution Medicines Be a Millionaire-Maker Stock? ↗
    The path for Revolution Medicines to grow an initial investment of $25,000 into $1 million is a daunting one. 
    Via The Motley Fool
    News headline image
    Merck (MRK) reports Q3: everything you need to know ahead of earnings
    Global pharmaceutical company Merck (NYSE:MRK) will be reporting earnings this Thursday before market open. Here’s what investors should know. Merck beat ana... 
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    Merck and Moderna's Cancer Vaccine Worked—Who Gets Paid? ↗
    Merck and Moderna's melanoma vaccine cut recurrence risk 42% in a Phase 3 trial, but results fell short of hopes, sending Moderna shares down sharply while Merck stock barely moved. 
    Via MarketBeat
    News headline image
    Merck Highlights Phase III Cancer Wins, Eyes 2027 Oncology Pipeline Catalysts ↗
    Merck & Co., Inc. (NYSE:MRK) outlined new oncology data and development plans at the European Society for Medical Oncology annual meeting, highlighting phase III results for its sacituzumab... 
    Via MarketBeat
    S&P 500 Top Movers: Gainers and Losers in Today's US Session ↗
    Via Chartmill
    Topics Stocks
    News headline image
    Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts ↗
    MercadoLibre, Novo Nordisk, Tyler Technologies and Summit Therapeutics trade below recent highs, yet each has earnings or catalysts that could shift sentiment. 
    Via MarketBeat
    Topics Artificial Intelligence
    News headline image
    KEYTRUDA® (pembrolizumab) as Monotherapy Reduced the Risk of Disease Progression or Death by 43% for Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Sacituzumab Tirumotecan (Sac-TMT) Reduced the Risk of Death by 32% and the Risk of Disease Progression or Death by 41% Compared to Chemotherapy in Certain Patients With Advanced or Recurrent Endometrial Cancer
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    A Personalized Cancer Therapy Delivered Positive Phase 3 Results; The Next Race Is Picking Better Targets
    News Provided by Biotech Insider on behalf of MindWalk Holdings Corp. 
    From Biotech Insider
    Via GlobeNewswire
    News headline image
    3 Stocks With Yields Big Enough to Make Election Volatility Easier to Stomach ↗
    Lincoln National, AbbVie and Phillips 66 offer dividends that pay investors through midterm volatility, backed by rising rates, steady drug demand and oil risk. 
    Via MarketBeat
    News headline image
    Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar Market
    Growing investment in next-generation CNS cancer therapies is driving research into targeted drugs, immunotherapy and new approaches to treating aggressive brain tumors. 
    From FN Media
    Via GlobeNewswire
    News headline image
    Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar Market
    EQNX::TICKER_START (NASDAQ:NTHI),(NASDAQ:NBIX),(NASDAQ:ACAD),(NASDAQ:AVXL),(NYSE:MRK) EQNX::TICKER_END 
    Via FinancialNewsMedia
    News headline image
    Not Lilly. Not Johnson & Johnson. This Stock Will Be the Biggest Healthcare Winner of 2026 ↗
    The market has rewarded this biotech for its breakthroughs. 
    Via The Motley Fool
    News headline image
    European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)
    From Merck & Co., Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    99 100 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.